Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Gild save search
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.24%
H: 0.71%
C: -0.87%
trodelvy phase 3
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
| Email alert
Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
Published: 2022-03-07 (Crawled : 14:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -2.66%
H: 0.0%
C: 0.0%
cs-02 cancer phase 3 breast cancer her2- her2 metastatic breast cancer
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Published: 2021-10-04 (Crawled : 06:00) - globenewswire.com
GLPGF | $35.5157 71.75% 4.8K
|
Health Technology
|
| O: -4.52%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.09%
H: 1.21%
C: -0.94%
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: -1.82%
H: 0.04%
C: -1.29%
disease phase 3 enroll
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
cancer phase 3 breast cancer als
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
Published: 2021-06-07 (Crawled : 23:00) - globenewswire.com
HOOK | $0.7695 0.92% 0.91% 170K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: -20.15%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.03%
H: 0.25%
C: 0.1%
phase 1 therapy cancer phase 3 phase 2 t-cell
HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO
Published: 2021-05-20 (Crawled : 12:15) - biospace.com/
HOOK | $0.7695 0.92% 0.91% 170K
|
Health Technology
|
| O: -2.84%
H: 0.54%
C: -9.78%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.23%
H: 1.92%
C: 1.0%
treatment phase 1 cancer phase 3 phase 2
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Published: 2021-04-28 (Crawled : 12:15) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -0.3%
H: 0.3%
C: -3.8%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.03%
H: 0.02%
C: -0.39%
phase 2 clinical trials phase 1 trial phase 3
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
Published: 2021-02-10 (Crawled : 14:03) - globenewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.06%
H: 1.58%
C: 0.04%
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: -13.39%
H: 2.15%
C: -5.04%
phase 3 trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.